Background-It is well established that hypertensive patients with left ventricular (LV) hypertrophy have impaired diastolic filling. However, the impact of antihypertensive treatment and LV mass reduction on LV diastolic filling remains unclear. Methods and Results-Echocardiograms were recorded in 728 hypertensive patients with ECG-verified LV hypertrophy (Cornell voltage-duration or Sokolow-Lyon) at baseline and after 1 year of blinded treatment with either losartan or atenolol-based regimen. Systolic and diastolic blood pressures (BP) were reduced on average 23/11 mm Hg; isovolumic relaxation time and E/A ratio became more normal, and LV inflow deceleration time prolonged (all PϽ0.001).
H ypertensive patients have a 2-to 3-fold higher risk of development of congestive heart failure than normotensive adults. 1 Furthermore, patients with congestive heart failure and normal left ventricular (LV) ejection fraction have a 4-fold increase in mortality rate. 2 There is evidence that hypertensive LV hypertrophy plays an important role in the development of heart failure. 3 We have shown that diastolic filling parameters are strongly related to LV hypertrophy and relative wall thickness (RWT) in hypertensive patients. 4 This might be a result of remodeling, muscle hypertrophy, and alterations of collagen structure. 5 Several animal and small human studies examining regression of LV hypertrophy and diastolic dysfunction in hypertensive patients showed that treatment-induced regression of LV hypertrophy did not decrease myocardial collagen levels or reduce the abnormal LV diastolic stiffness and hence improve LV diastolic filling. 6 -11 However, other small studies show improvement of diastolic filling parameters along with systolic and diastolic blood pressure (BP) and/or LV mass reduction. [12] [13] [14] Furthermore, studies in patients with diastolic dysfunction without concomitant LV hypertrophy have either shown no improvement 15 or improvement after multiyear antihypertensive treatment. 16 This might be a result of simultaneous changes in active LV relaxation and passive LV chamber stiffness. 17 To our knowledge, there are no large studies examining the effect of antihypertensive treatment on LV diastolic function in hypertensive patients. The aim of this study was to investigate changes in LV diastolic filling and their relation to regression of LV hypertrophy due to systematic antihypertensive treatment.
As part of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial, 18 Ͼ10% of study participants enrolled in a substudy in which echocardiograms are performed at study baseline and yearly thereafter. 4, 19, 20 This report uses the baseline and follow-up year-1 echocardiograms from this substudy to determine the effect of antihypertensive treatment on LV diastolic filling in hypertensive patients.
Methods
Patients gave informed consent, and the Committees of Ethical Science accepted this study. All patients had a screening ECG with LV hypertrophy by either sex-adjusted Cornell voltage duration Ն2440 mV · ms or Sokolow-Lyon voltage criteria Ͼ38 mV; exclusion criteria have been previously described. 18
Subjects
Eligible individuals were 960 hypertensive patients; 876 had echocardiograms at baseline and at year-1, as 84 follow-up studies were not performed because of death (nϭ10) or disability or failure to cooperate (nϭ74). A total of 148 participants in the echocardiography substudy were ineligible for the present study because of inability to obtain baseline and/or year-1 measurements of LV mass (nϭ19) or transmitral Doppler flow profiles (nϭ129). Compared with ineligible patients, the present study patients were younger at enrollment (mean 66.2Ϯ6.7 versus 68.4Ϯ7.7 years, PϽ0.01) but did not differ in sex distribution, body mass index, systolic or diastolic BP, LV mass, RWT, isovolumic relaxation time (IVRT), E/A ratio, or mitral valve deceleration time.
Echocardiographic Methods
Echocardiographic procedures for this study are previously described. 4, 19, 20 End-diastolic LV dimensions were used to calculate LV mass by an anatomically validated formula (rϭ0.90 versus necropsy LV mass). 21 RWT at end-diastole was calculated as end-diastolic posterior wall thickness/LV internal radius 22 ; RWT at end-systole was also calculated by a similar formula because this contributes to the LV geometric component of passive ventricular stiffness that is superimposed on the active process of myocardial relaxation in early diastole. LV hypertrophy was considered present when LV mass indexed for body surface area was Ͼ116 g/m 2 for men and Ͼ104 g/m 2 for women. 23 Increased diastolic RWT was present when this ratio was Ͼ0.430. 24 LV geometry definitions 19 and methods of pulsed Doppler recordings 4 have previously been described.
Statistics
Statistical software (SPSS Version 9.0, SPSS, Inc) was used for statistical analysis. Results are meanϮSD when appropriate, and frequencies are expressed as percentages. Differences in continuous variables between two groups were assessed by Student's t test for parametric data and by 2 analysis for categorical data; comparison among multiple groups was performed by ANOVA with the Scheffé post hoc test.
A study from the Reading Center showed that LV mass on serial echocardiograms has high reliability and little regression to the mean. 25 Between-study LV mass change of Ϯ35 g or Ϯ17 g had Ն95% or Ն80% likelihood of being true change. Explanatory analyses dichotomized patients at LV mass reduction partitions of Ϫ35 and Ϫ17 g, respectively, from baseline values. However, this did not alter any conclusions (data not shown). Therefore, patients were dichotomized to whether LV mass decreased or, alternatively, either remained unchanged or increased. Independent correlates of continuous measures of LV transmitral flow patterns were identified by multiple linear regression analysis with an enter procedure with assessment of colinearity diagnostics. A value of PϽ0.05 (2-tailed) was considered statistically significant.
Results

Patient Characteristics
Descriptive data of the whole LIFE population 18 and LV diastolic function at baseline in the LIFE echocardiography substudy have been reported elsewhere. 4 Of the total 960 patients, 728 patients had paired imaging and Doppler measurements at baseline, and year-1 follow-up was needed for inclusion in the present study. Mean age was 67Ϯ7 years, and 41% were women.
Changes in Left Atrial and Ventricular Structure and Diastolic Function
As shown in Table 1 , mean end-echo BPs were reduced by 23/11 mm Hg (PϽ0.001). Mean LV mass was reduced by Ϸ12%. The reduction of LV mass was due to reduction of interventricular septal, posterior wall, and end-diastolic RWT by Ϸ10%. Furthermore, we found an Ϸ9% reduction in end-systolic RWT and an Ϸ3% reduction in left atrial size. However, LV internal diameter in diastole increased by Ͻ1%, as did mean body mass index. IVRT shortened and the E/A ratio increased; deceleration time increased by Ϸ7% and atrial filling fraction decreased by Ϸ10%.
Change in Left Ventricular Filling Patterns
At baseline, abnormal relaxation was by far the most common abnormal transmitral flow pattern, whereas 15% had normal mitral valve flow profile, 11% had pseudonormal flow profile, and only 5% had restrictive flow pattern ( Figure 1 ). After 1 year of treatment, the prevalence of normal flow pattern increased to Ϸ26% and abnormal relaxation decreased to 57%. The prevalence of pseudonormal pattern decreased to Ϸ5%, whereas the restrictive pattern prevalence changed little (PϽ0.05).
LV Hypertrophy Regression and Diastolic Filling
Comparing patients with LV mass decrease and those with no decrease or an increase in LV mass, patients with LV mass decrease had the same reduction in systolic and diastolic BP ( Table 1) as well as in mean BP ( Figure 2 ) and a slight increase in body mass index (PϽ0.05), compared with patients without LV mass reduction.
Patients with LV mass regression had significant reduction in left atrial diameter, shortened IVRT, increased E/A ratio, prolonged mitral valve deceleration time, and decreased atrial filling fraction. Patients without change or with increase in LV mass, after 1 year of antihypertensive treatment, had no change in left atrial size, IVRT, E/A ratio, or mitral valve deceleration time but had decreased mean atrial filling fraction from baseline values ( Table 1 ). In an analysis of the changes between baseline and year-1 values, patients with LV mass reduction, compared with patients without LV mass reduction, had significantly greater reduction in left atrial size and in IVRT but similar changes in E/A ratio, mitral valve deceleration time, and atrial filling fraction (Table 1) .
Patients with reduction of end-diastolic RWT (nϭ561) had significantly reduced left atrial size (3.92Ϯ0.53 to 3.79Ϯ0.56 cm), shortened IVRT (117Ϯ24 to 104Ϯ22 ms), increased E/A ratio (0.84Ϯ0.31 to 0.93Ϯ0.34), prolonged mitral valve deceleration time (219Ϯ65 to 234Ϯ69 ms), and decreased atrial filling fraction (0.42Ϯ0.10 to 0.38Ϯ0.12, all PϽ0.001) from baseline values after 1 year of antihypertensive treatment. Patients without change or with increase in end-diastolic RWT after 1 year of antihypertensive treatment (nϭ167) had no change in IVRT (112Ϯ27 to 108Ϯ20 ms), E/A ratio (0.89Ϯ0.42 to 0.90Ϯ28), deceleration time (215Ϯ67 to 220Ϯ51 ms), and atrial filling fraction (0.42Ϯ0.10 to 0.40Ϯ0.11, all PϭNS) but had reduced left atrial size (4.00Ϯ0.63 to 3.89Ϯ0.56, PϽ0.05) from baseline values. Patients with end-diastolic RWT reduction, compared with patients without end-diastolic RWT reduction, had significantly greater IVRT shortening (Ϫ12.4Ϯ29 versus Ϫ4.0Ϯ32 ms, respectively, PϽ0.01), E/A ratio increase (0.09Ϯ0.32 versus 0.02Ϯ0.32, PϽ0.05), and atrial filling fraction decrease (Ϫ0.05Ϯ0.11 versus Ϫ0.02Ϯ0.12, PϽ0.001) but similar changes of left atrial size (Ϫ0.10Ϯ0.59 versus Ϫ0.13Ϯ0.49 cm) and mitral valve deceleration time (14.4Ϯ83 versus 4.5Ϯ74 ms, both PϭNS).
Correlates of Changes in Diastolic Filling Parameters
Univariate analyses (Table 2) showed that shortened IVRT was related to younger age and reductions in LV mass and end-diastolic and end-systolic RWT and left atrial dimension. Multivariate analyses yielded a model (Rϭ0.257, PϽ0.001) in which younger age (␤ϭ0.74, Pϭ0.05) and reductions in LV mass (␤ϭ0.123), left atrial diameter (␤ϭ0.120), and end-diastolic RWT (␤ϭ0.112, all PϽ0.01) were independently associated with IVRT reduction. In an alternative (Table 2) showed that increase in E/A ratio correlated with reduction in BP, prolonged IVRT, and increase in LV internal diameter in diastole and end-diastolic RWT but not end-systolic RWT. Multivariate analysis yielded a model (Rϭ0.204) in which increased E/A ratio was independently associated with reduced diastolic arterial BP (␤ϭϪ0.137), prolonged IVRT (␤ϭϪ0.110, all PϽ0.01), and reduction in end-diastolic RWT (␤ϭϪ0.082, PϽ0.05).
Univariate analysis ( Table 2 ) showed that prolonged deceleration time correlated with smaller end-systolic RWT, smaller left atrial dimension, and smaller E/A ratio. Multivariate analyses (Rϭ0.171) showed that prolongation of mitral valve deceleration time was independently associated with reduced end-systolic RWT (␤ϭ0.082), E/A ratio (␤ϭ0.078, both PϽ0.05), and left atrial dimension (␤ϭ0.112, PϽ0.01).
Final univariate analysis ( Table 2) showed that reduction in atrial filling fraction correlated with reduced diastolic BP, end-diastolic RWT, and E/A ratio, shortened deceleration time and time-velocity integral, and increased LV internal dimension. Reduced atrial filling fraction was independently associated with both decreased diastolic BP (␤ϭ 0.116) and increased LV internal dimension (␤ϭ-0.102, both PϽ0.01) in multivariate analysis (Rϭ0.160, PϽ0.001 ).
Discussion
This study provides the first assessment of the relation of changes in LV geometry to changes in diastolic LV function during antihypertensive treatment in a large series of hypertensive patients with ECG-verified LV hypertrophy. This study shows four new observations. Antihypertensive treatment resulting in Ϸ10% reduction in LV mass results in a 3% reduction in left atrial diameter, 9% shortened IVRT, and 10% decrease in atrial filling fraction, and 9% and 7% increases in E/A ratio and mitral valve deceleration time, respectively. The apparent paradoxical prolongation of the mitral valve deceleration time with shortening of IVRT may be due to improved active relaxation and reduction of passive chamber stiffness associated with reduction of end-systolic RWT 26 as well as probable normalization of connective tissue. 17, 27 Our results support the finding by Yalcin and coworkers 28 that 6 months antihypertensive treatment with perindopril led to reduction in LV mass and left atrial volume and increased E/A ratio. However, our study contrasts with a study by Cuspidi et al 7 in a smaller population (nϭ39) in which 6 months of antihypertensive treatment had no significant effect on LV diastolic filling parameters.
Reduction of LV mass and RWT by Ϸ10% are associated with an increase in the proportion of the patients with normal mitral valve flow pattern by 73%, reduction of abnormal relaxation by 17%, and of the pseudonormal pattern by 60%, with almost no change in restrictive pattern. The antihypertensive treatment normalized LV filling parameters in 20% of patients, whereas 10% had LV filling abnormalities and 69% remained unchanged.
Another major observation is that patients with reduction in LV mass, as opposed to no change or an increase in LV mass, had shortening of IVRT, reductions in left atrial dimension and atrial filling fraction, and increase in E/A ratio and mitral valve deceleration time, whereas no change in diastolic filling parameters was seen in patients without LV mass reduction. In parallel, patients with reduction of end-di- astolic RWT, compared with patients without RWT reduction, had shortening of IVRT, reduction of in left atrial dimension and atrial filling fraction, and increase in E/A ratio and mitral valve deceleration time. Finally, shortening of IVRT is independently associated with LV mass reduction. Increase in E/A ratio is independently associated with reduction in diastolic BP, and finally, increase in mitral valve deceleration time is independently associated with decreased in mitral valve deceleration time. This corresponds well with what is found in dogs, 17 patients with aortic stenosis and aortic valve replacement, 29 and hypertensive patients without LV hypertrophy who had RWT regression. 16 Decrease in hemodynamic overload and remodeling of the myocardium have been associated with a decrease in muscle mass but a "relative" increase in fibrous tissue, which regresses less rapidly than myocardial tissue, necessitating 7 years for normalization of myocardial stiffness in one study. 29 
Clinical Implications
Regression of hypertensive LV hypertrophy and of concentric LV geometry is associated with partial normalization of several LV diastolic filling parameters, including the IVRT, E/A-ratio and atrial filling fraction. In multivariate analyses, the associations were independent of the reduction in BP, indicating direct effects of normalization of LV geometry on diastolic filling parameters. The complexity of factors influencing LV diastolic filling is highlighted by the fact that the deceleration time of early diastolic filling passive inflow increased at the same time as the as the IVRT decreased. This implies that the deceleration time at enrollment in the LIFE echocardiography study was effected in opposite directions, being lengthened by impaired relaxation and shortened by increased LV stiffness due to increased relative wall thickness and probable alterations in myocardial connective tissue. A strong relation between invasively-measured early diastolic chamber stiffness and shortened deceleration time was reported in an experimental study by Little et al 17 and in a human study by Garcia et al. 30 Treatment improved relaxation predominated in shortening the IVRT while reducing chamber stiffness predominated by prolonging the deceleration time of early diastolic transmitral flow. The improvement of diastolic dysfunction parameters may contribute to the ability of BP reduction to prevent congestive heart failure and highlights the role of antihypertensive therapy in primary prevention of congestive heart failure in hypertensive patients with LV hypertrophy. 31
Limitations of the Study
Data are analyzed in patients with ECG-verified LV hypertrophy, of whom 70% had echocardiographically verified LV hypertrophy. Hence, our data may be representative of patients with LV mass in the hypertrophied or high normal range. No attempts were made to measure LV filling pressures, although it is likely that in outpatients volunteering for a long-term treatment trial, they are in a relatively narrow range of normal to mildly elevated levels. To simplify the protocol, no measurements of pulmonary venous flow were made, making it possible that the group with normal diastolic dysfunction may contain patients who should be classified as "pseudonormal" and visa versa. The antihypertensive treatment regime is at the moment blinded and will remain so until the LIFE study ends. Furthermore, because of the known effect of ␤-blockers to reduce heart rate, the LIFE Steering Committee has decided that change in heart rate during treatment cannot be reported until the study is unblinded. Therefore it was not possible to report findings in relation to treatment with either atenolol or losartan. However, ␤-blockade has been shown to increase the deceleration time of early diastolic transmitral flow in patients with dilated cardiomyopathy. 32 Therefore, where appropriate, data were controlled for heart rate (data not shown), and this did not alter any conclusions.
